CY1107451T1 - Υδροβρωμικον escitalopram και μεθοδος δια την παρασκευη αυτου - Google Patents

Υδροβρωμικον escitalopram και μεθοδος δια την παρασκευη αυτου

Info

Publication number
CY1107451T1
CY1107451T1 CY20081100470T CY081100470T CY1107451T1 CY 1107451 T1 CY1107451 T1 CY 1107451T1 CY 20081100470 T CY20081100470 T CY 20081100470T CY 081100470 T CY081100470 T CY 081100470T CY 1107451 T1 CY1107451 T1 CY 1107451T1
Authority
CY
Cyprus
Prior art keywords
escitalopram
hydrobromic
preparing
citalopram
hydrobromide
Prior art date
Application number
CY20081100470T
Other languages
Greek (el)
English (en)
Inventor
Lawrence Martel
Robert Dancer
Hans Petersen
Peter Ellegaard
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32668635&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1107451(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of CY1107451T1 publication Critical patent/CY1107451T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CY20081100470T 2002-12-23 2008-05-02 Υδροβρωμικον escitalopram και μεθοδος δια την παρασκευη αυτου CY1107451T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200202005 2002-12-23
EP03779759A EP1578738B1 (en) 2002-12-23 2003-12-18 Escitalopram hydrobromide and a method for the preparation thereof

Publications (1)

Publication Number Publication Date
CY1107451T1 true CY1107451T1 (el) 2012-12-19

Family

ID=32668635

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100470T CY1107451T1 (el) 2002-12-23 2008-05-02 Υδροβρωμικον escitalopram και μεθοδος δια την παρασκευη αυτου

Country Status (32)

Country Link
US (1) US20040167209A1 (cg-RX-API-DMAC7.html)
EP (1) EP1578738B1 (cg-RX-API-DMAC7.html)
JP (2) JP4658613B2 (cg-RX-API-DMAC7.html)
KR (1) KR20050086933A (cg-RX-API-DMAC7.html)
CN (1) CN100349885C (cg-RX-API-DMAC7.html)
AR (1) AR042652A1 (cg-RX-API-DMAC7.html)
AT (1) ATE388947T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003287919B2 (cg-RX-API-DMAC7.html)
BR (1) BR0317623A (cg-RX-API-DMAC7.html)
CA (1) CA2511142A1 (cg-RX-API-DMAC7.html)
CY (1) CY1107451T1 (cg-RX-API-DMAC7.html)
DE (1) DE60319739T2 (cg-RX-API-DMAC7.html)
DK (1) DK1578738T3 (cg-RX-API-DMAC7.html)
EA (1) EA013116B1 (cg-RX-API-DMAC7.html)
EG (1) EG24729A (cg-RX-API-DMAC7.html)
ES (1) ES2298595T3 (cg-RX-API-DMAC7.html)
IL (1) IL169125A0 (cg-RX-API-DMAC7.html)
IS (1) IS2654B (cg-RX-API-DMAC7.html)
ME (1) MEP5808A (cg-RX-API-DMAC7.html)
MX (1) MXPA05005772A (cg-RX-API-DMAC7.html)
MY (1) MY135468A (cg-RX-API-DMAC7.html)
NO (1) NO20053595L (cg-RX-API-DMAC7.html)
NZ (1) NZ540281A (cg-RX-API-DMAC7.html)
PE (1) PE20040924A1 (cg-RX-API-DMAC7.html)
PL (1) PL378275A1 (cg-RX-API-DMAC7.html)
PT (1) PT1578738E (cg-RX-API-DMAC7.html)
RS (1) RS51092B (cg-RX-API-DMAC7.html)
TW (1) TW200501943A (cg-RX-API-DMAC7.html)
UA (1) UA80170C2 (cg-RX-API-DMAC7.html)
UY (1) UY28148A1 (cg-RX-API-DMAC7.html)
WO (1) WO2004056791A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200504109B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
NZ540281A (en) * 2002-12-23 2008-07-31 Lundbeck & Co As H Escitalopram hydrobromide and a method for the preparation thereof
NZ549100A (en) * 2004-03-05 2010-02-26 Lundbeck & Co As H Crystalline composition containing escitalopram oxalate
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
TWI358407B (en) * 2005-06-22 2012-02-21 Lundbeck & Co As H Crystalline base of escitalopram and orodispersibl
KR20080080094A (ko) * 2005-10-14 2008-09-02 하. 룬트벡 아크티에 셀스카브 에스시탈로프람 및 부프로피온의 저용량 조합물을 이용한중추신경계 장애의 치료 방법
AU2006304889A1 (en) * 2005-10-14 2007-04-26 H. Lundbeck A/S Stable pharmaceutical formulations containing escitalopram and bupropion
TW200812993A (en) * 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
EP2042499B1 (en) * 2006-07-11 2018-06-27 Mitsubishi Tanabe Pharma Corporation Salt of a morpholine compound
WO2008059514A2 (en) * 2006-07-31 2008-05-22 Cadila Healthcare Limited Process for preparing escitalopram
FR3006594A1 (fr) * 2013-06-11 2014-12-12 Sorin Crm Sas Microsonde implantable de detection/stimulation incorporant un agent anti-inflammatoire
CN108976188B (zh) * 2017-06-05 2022-12-06 上海奥博生物医药股份有限公司 一种艾司西酞普兰双羟萘酸盐新的制备方法
AU2018349284B2 (en) * 2017-10-09 2023-11-16 428 Pharma BV. New salt and solid state forms of escitalopram
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US34712A (en) * 1862-03-18 James h
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
WO2000023431A1 (en) * 1998-10-20 2000-04-27 H. Lundbeck A/S Method for the preparation of citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
HK1043129B (zh) * 1999-10-25 2004-10-21 H‧隆德贝克有限公司 西酞普蘭的製備方法
JP2002020379A (ja) * 2000-05-02 2002-01-23 Sumika Fine Chemicals Co Ltd シタロプラム臭化水素酸塩の結晶およびその結晶化方法
US6977306B2 (en) * 2000-05-02 2005-12-20 Sumitomo Chemical Company, Limited Citalopram hydrobromide crystal and method for crystallization thereof
CA2353693C (en) * 2000-08-10 2003-07-22 H. Lundbeck A/S Pharmaceutical composition containing citalopram
ES2223959T3 (es) * 2000-12-04 2005-03-01 Westfalia Separator Ag Procedimiento de pretratamiento de aceites en bruto y grasas en bruto para la produccion de esteres de acidos grasos.
CA2445843A1 (en) * 2001-05-01 2002-11-07 H. Lundbeck A/S The use of enantiomeric pure escitalopram
AR034612A1 (es) * 2001-06-25 2004-03-03 Lundbeck & Co As H Proceso para la preparacion del citalopram racemico y/o del s- o r-citalopram mediante la separacion de una mezcla de r- y s-citalopram
NZ540281A (en) * 2002-12-23 2008-07-31 Lundbeck & Co As H Escitalopram hydrobromide and a method for the preparation thereof
US20050174782A1 (en) * 2003-03-25 2005-08-11 Chapman Leonard T. Flashlight

Also Published As

Publication number Publication date
NZ540281A (en) 2008-07-31
MXPA05005772A (es) 2005-08-16
ES2298595T3 (es) 2008-05-16
EP1578738B1 (en) 2008-03-12
EG24729A (en) 2010-06-21
CA2511142A1 (en) 2004-07-08
EA013116B1 (ru) 2010-02-26
IL169125A0 (en) 2009-02-11
BR0317623A (pt) 2005-11-29
US20040167209A1 (en) 2004-08-26
MEP5808A (xx) 2010-02-10
DE60319739D1 (de) 2008-04-24
JP2006514952A (ja) 2006-05-18
ZA200504109B (en) 2006-08-30
MY135468A (en) 2008-04-30
AR042652A1 (es) 2005-06-29
KR20050086933A (ko) 2005-08-30
AU2003287919A1 (en) 2004-07-14
JP2011037893A (ja) 2011-02-24
UA80170C2 (en) 2007-08-27
ATE388947T1 (de) 2008-03-15
RS51092B (sr) 2010-10-31
IS2654B (is) 2010-08-15
JP4658613B2 (ja) 2011-03-23
IS7848A (is) 2005-05-17
PL378275A1 (pl) 2006-03-20
UY28148A1 (es) 2004-09-30
AU2003287919B2 (en) 2009-11-12
DK1578738T3 (da) 2008-06-30
HK1087708A1 (en) 2006-10-20
RS20050487A (sr) 2007-06-04
CN1726202A (zh) 2006-01-25
PE20040924A1 (es) 2004-12-11
EP1578738A1 (en) 2005-09-28
NO20053595L (no) 2005-09-05
PT1578738E (pt) 2008-04-11
EA200501046A1 (ru) 2005-12-29
TW200501943A (en) 2005-01-16
WO2004056791A1 (en) 2004-07-08
DE60319739T2 (de) 2008-07-17
CN100349885C (zh) 2007-11-21

Similar Documents

Publication Publication Date Title
DE50202328D1 (de) Amidofunktionelle aminopolydiorganosiloxane
FR2841900B1 (fr) Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
NO331093B1 (no) Somatostatinanaloger, fremgangsmåte for fremstilling, farmasøytisk sammensetning og anvendelse derav.
CY2017009I2 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1112687T1 (el) Μεθοδος για χρηση δικετοπιπεραζινων και συνθεσεις που περιλαμβανουν αυτες
CY2014038I2 (el) Αντι-il-6 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1112862T1 (el) Θραυσματα μονοσθενους αντισωματος χρησιμα ως θεραπευτικα
NO20052496D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
TNSN05254A1 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
EP1526120A3 (en) Concrete surface retarders
ATE415817T1 (de) Agrochemische formulierungen
ITMO20030057A0 (it) Dispositivo per la confezione,la miscelazione e l'applicazione di cemento osseo.
CY2009017I2 (el) Μεθοδος για την παρασκευη 10, 11-διυδρο-10-υδροξυ-5η-διβενζο/β,f/αζεπινο-5-καρβοξαμιδιου και 10,11-διυδρο-10-οξο-5η-διβενζο/β,f/αζεπινο-5-καρβοξαμιδιου
GB0320020D0 (en) Improved formulation for providing an enteric coating material
TW200501943A (en) Escitalopram hydrobromide and a method for the preparation thereof
DE50204688D1 (de) N-alkylaziridinoprepolymere als dentalmasse
ITRM20030363A0 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico diesse.
NO20070351L (no) Materialer og fremgangsmater for forbedring av skalldyrhelse, -immunitet og -vekst
BR0109180A (pt) Método para a preparação de 5-ciano-1-(4-fluorofenil) -1,3- diidroisobenzofuranos e composição farmacêutica de antidepressivo
DK1406642T3 (da) Fremgangsmåde til polyvalent bakteriofag-fremstilling til behandling af bakterielle infektioner
AU2003236118A1 (en) An antispastic, analgetic pharmaceutical composition and the preparation method thereof as well as the quality control technique therefor
ITRM20000266A0 (it) Procedimento migliorato per la preparazione di (e,z) 3-(2-amminoetossimmino)-androstano-6, 17-dione e di suoi analoghi.
NO20031108D0 (no) Farmasöytisk preparat for behandling av hodepine, og fremgangsmåte for fremstilling av preparatet
DK1537132T3 (da) Salt af mortin-6-glucuronid
PT1408035E (pt) Metodo de preparacao de derivativos de 1.5-diaril-3-trifluorometilo-delta2-pirazolinas que sejam racemicos e enanciomericamente puros